media Media
Press Releases2020-05-07T14:51:44+00:00

Press Releases

Amid the COVID-19 Pandemic, Neurologists in Canada Report Pulling Back from EMD Serono’s Mavenclad and Sanofi Genzyme’s Lemtrada, While Roche’s Ocrevus Stalls, According to Spherix Global Insights

Use in treatment-naïve patients drives recent growth of Biogen’s Tecfidera and Genzyme’s Aubagio in Canada, as reported switch share has remained flat over the past year – reflecting the continued shift in using established oral agents earlier in the multiple sclerosis treatment algorithm

May 27, 2020|

Switching Patterns Among Relapsing-Remitting Multiple Sclerosis: Genentech’s Ocrevus on the Rise, Biogen’s Tecfidera Declines, and Teva’s Copaxone Remains Strong, According to Spherix Global Insights

Is there trouble in paradise for Genentech? US neurologist reevaluation of Ocrevus in PPMS patients, along with competitive pressure from Bristol Myers Squibb’s Zeposia, Novartis’ ofatumumab, and Janssen’s ponesimod, will further test the resiliency of the current leaders in the switch segment EXTON, Pa., April 30, 2020/PRNewswire/ — Genentech’s Ocrevus, Teva’s Copaxone, and Biogen’s Tecfidera score the top three share positions among patients who recently switched to a different disease-modifying therapy (DMT). The diverse clinical profiles of the current share [...]

April 30, 2020|

UCB’s Cimzia is Making Inroads in the Treatment of Axial Disease, with Significant Uptake in Non-Radiographic Axial Spondyloarthritis and a Positive Treatment Halo in Ankylosing Spondylitis

In AS, the IL-17 inhibitors are beginning to challenge the leading TNF inhibitors, but rheumatologists struggle to differentiate Novartis’ Cosentyx and Eli Lilly’s Taltz, according to a new report by Spherix Global Insights EXTON, Pa., April 29, 2020 /PRNewswire/ — The recent approval of UCB’s TNF inhibitor, Cimzia, for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) has reinvigorated a somewhat dull treatment landscape, while the IL-17 inhibitors continue to carve a niche for themselves in the treatment of ankylosing [...]

April 29, 2020|